Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Cancer

Publication
Video
Special ReportsHead and Neck Cancers (Issue 4)
Volume 3
Issue 4

Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.

Ramona Dadu, MD, endocrinologist, MD Anderson Cancer Center, discusses the benefits of using immunotherapies in thyroid cancer and some of the potential drawbacks that coincide with the treatments. Dadu says immunotherapies could afford patients with thyroid cancer an elongated progression free survival, potentially less toxicities, and most importantly an extensive overall survival benefit.

Articles in this issue
Immunotherapies Gaining Traction in Head and Neck Cancers
Immunotherapies Gaining Traction in Head and Neck Cancers
Patient-Derived Xenografts Could Personalize Anaplastic Thyroid Cancer Care
Patient-Derived Xenografts Could Personalize Anaplastic Thyroid Cancer Care
Dr. Sylvia Asa on Treating Different Types of Thyroid Cancer
Link Drawn Between Oral HPV and Risk of Head and Neck Cancers
Link Drawn Between Oral HPV and Risk of Head and Neck Cancers
Ilaria Muller on a Possible Common Antigen Between Thyroid and Breast Cancers
Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Cancer
Dr. Ramona Dadu on Immunotherapies and Their Role in Thyroid Cancer
Nivolumab Could Change Head and Neck Cancer Treatment Paradigm
Nivolumab Could Change Head and Neck Cancer Treatment Paradigm
Nivolumab Boosts OS in Phase III in SCCHN Study
Nivolumab Boosts OS in Phase III in SCCHN Study
Related Videos
Related Content
Survival Benefit Continues With Fixed-Duration Venetoclax in CLL

Survival Benefit Continues With Fixed-Duration Venetoclax in CLL

November 28th 2023
Article

In the phase 3 MURANO trial, there was a continued survival benefit in patients with chronic lymphocytic leukemia treated with fixed-duration venetoclax plus rituximab.

Read More

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

Mitigating Cardiotoxicity Resulting from Immune Checkpoint Inhibitor Therapy

June 30th 2023
Podcast

In season 4, episode 9 of Targeted Talks, Kerry Reynolds, MD, discusses the occurrence of myocarditis in patients with cancer treated with immune checkpoint inhibitors.

Listen

Pirtobrutinib Inhibits BTK C481 Clones in Patients With CLL

Pirtobrutinib Inhibits BTK C481 Clones in Patients With CLL

November 27th 2023
Article

Among patients with chronic lymphocytic leukemia who progressed after treatment, pirtobrutinib demonstrated a clearance of BTK C481 clones and the development of non-C481 clones.

Read More

Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

Anticipating Novel Options for the RAI-Refractory DTC Armamentarium

May 15th 2023
Podcast

In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.

Listen

Context of Gender May Influence Fears Related to Low-Risk PTC

Context of Gender May Influence Fears Related to Low-Risk PTC

November 25th 2023
Article

Read More

Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment

Park Considers Long-Term Data for Frontline Metastatic ccRCC Treatment

November 24th 2023
Article

During a Targeted Oncology™ Case-Based Roundtable™ event, Chandler Park, MD, reviewed the latest updates of the pivotal trials of frontline combination therapies for advanced clear cell renal cell carcinoma.

Read More